VBI Vaccines Inc.
NASDAQ:VBIV 4:00:00 PM EDT
Market Cap (Intraday) | 14.27M |
Current PE | N/A |
Forward PE | N/A |
2yr Forward PE | N/A |
10-Day MA | $0.58 |
50-Day MA | $0.61 |
200-Day MA | $0.92 |
VBI Vaccines Inc. Stock, NASDAQ:VBIV
160 2nd Street, Floor 3, Cambridge, Massachusetts 02142
United States of America
Phone: +1.617.830.3031
Number of Employees: 190
Description
VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, Sci-B-Vac and VBI-2601. It also develops an enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on April 9, 1965 and is headquartered in Cambridge, MA.